

Esperanza Muñoz Muela

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4996892/publications.pdf>

Version: 2024-02-01

7
papers

193
citations

1478505

6
h-index

1872680

6
g-index

7
all docs

7
docs citations

7
times ranked

311
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trial. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1151.e9-1151.e16.	6.0	6
2	Deciphering the quality of SARS-CoV-2 specific T-cell response associated with disease severity, immune memory and heterologous response. <i>Clinical and Translational Medicine</i> , 2022, 12, e802.	4.0	8
3	Clinical, laboratory data and inflammatory biomarkers at baseline as early discharge predictors in hospitalized SARS-CoV-2 infected patients. <i>PLoS ONE</i> , 2022, 17, e0269875.	2.5	0
4	Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2128-2139.	10.5	81
5	Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1 β , Early Predictors of Severe COVID-19. <i>Microorganisms</i> , 2021, 9, 2259.	3.6	14
6	Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/ β -catenin and TGF β signaling pathways. <i>European Journal of Nutrition</i> , 2019, 58, 3207-3219.	3.9	42
7	Activating Transcription Factor 4 Modulates TGF β -Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling. <i>Clinical Cancer Research</i> , 2018, 24, 5697-5709.	7.0	42